Olaparib (AZD2281, Ku-0059436)

目录号:S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436)是选择性的PARP1/2抑制剂,IC50为5 nM/1 nM,其对PARP1/2的作用比对Tankyrase-1效果高300倍。

规格 价格 库存 购买数量  
RMB 745.41 现货
RMB 571.54 现货
RMB 1219.52 现货
RMB 3019.32 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献79篇:

客户使用该产品的17个实验数据:

  • CYREN does not regulate repair of replication-induced DSBs. Representative images of chromosomes.

    Nature, 2017, 549(7673):548-552. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Clonogenic survival of cells expressing BARD1(WT)res or BARD1(AAE)res after treatment with olaparib or MMC. Data are means ± s.d., n = 3. EV, empty vector. P values were calculated using two-way ANOVA and multiple comparisons were corrected by the Bonferroni method. ** P < 0.01.

    Nature, 2017, 550(7676):360-365. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Western blot analysis showing PARylated proteins in cells subject to the indicated PARP inhibitor treatments (5 μM Olaparib and 10 μM NU1025).

    Cell, 2017. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • (A) Representative confocal microscopy images of nuclear γ-H2AX (red) and DAPI (blue) staining in FKO1 cells 30 minutes following irradiation. Cells pre-treated for 24hr with 1μM NanoOlaparib, olaparib, or a vehicle control before irradiation.

    Mol Cancer Ther, 2017. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

产品安全说明书

PARP抑制剂选择性比较

生物活性

产品描述 Olaparib (AZD2281, KU0059436)是选择性的PARP1/2抑制剂,IC50为5 nM/1 nM,其对PARP1/2的作用比对Tankyrase-1效果高300倍。
特性 Olaparib是第一批PARP抑制剂之一。
靶点
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
1 nM 5 nM
体外研究

Olaparib是PARP抑制剂,也作用于BRCA1或BRCA2突变。Olaparib对端锚(聚合)酶-1作用效果不大,IC50值大于。Olaparib浓度为30-100 nM作用于SW620细胞,使PARP-1失活。与BRCA1和BRCA2充足细胞系(Hs578T,MDA-MB-231,T47D)相比,BRCA1缺陷细胞系(MDA-MB-463和HCC1937)对Olaparib过分敏感[1] Olaparib抑制PARP,阻断碱基切除修复,导致KB2P细胞对Olaparib强烈敏感。结果导致在DNA复制时由单链断裂转变为双链断裂,由此激活BRCA2依赖的重组途径。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnGTo94PCCm NVPhPW52UUN3ME21MlcxPSBizszNJC=> MorkNVg2PTl4MUO=
KP6.3 M{H5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYWxfJdTPCCm MY\JR|UxRTFyLkSyPEDPxE1i NEW1b3QyQDV3OU[xNy=>
KP7.7 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\wOEBl NGjlWXVKSzVyPUW3JI5OKA>? M4C5d|E5PTV7NkGz
KB2P3.4 M3nVZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnPcY05PCCm Ml3KTWM2OD1zMkSgUUA> M{H4d|E5PTV7NkGz
KB2P1.21 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWq0JIQ> MorkTWM2OD16OUC3JI5OKA>? MWKxPFU2QTZzMx?=
U373-MG NIPwbYFEgXSxdH;4bYMhSXO|YYm= MVixJO69VSB? MmLnNlQhcA>? NFLVVHFKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 NU\w[XVGOTh7NUS3NVI>
T98G MUnDfZRwfG:6aXOgRZN{[Xl? M1vaNFEh|ryPIB?= NY\scWtvOjRiaB?= MmrDTY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? NVHBVFhxOTh7NUS3NVI>
U87-MG NFjKZ2NEgXSxdH;4bYMhSXO|YYm= MYCxJO69VSB? Mm\JNlQhcA>? MofwTY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? M2X1[|E5QTV2N{Gy
UVW M1zRdWN6fG:2b4jpZ{BCe3OjeR?= MW[1NFAhdk1? NWKzOWRrOjRiaB?= NETjc4NKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 MoniNVg6PTR5MUK=
HeLa NGH5Z4tHfW6ldHnvckBCe3OjeR?= M3fBZ|UxOCCwTR?= NUnEOmpTPCCq NEDicWZE[XW|ZYOgZUBud2Snc4Sg[IVt[XliaX6gdoVrd2mwaX7nJI9nKHKjZHnheIlwdi2rbnT1Z4VlKESQQTDidoVic3N? NWW2ZolrOTh7NUS3NVI>
HeLa NIPzNXdHfW6ldHnvckBCe3OjeR?= M3r3WFEh|ryPIB?= MVuyOEBp M1\ONmVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJHMueGijc3WgZZJz\XO2 MXOxPFk2PDdzMh?=
T98G NYPTRW5pTnWwY4Tpc44hSXO|YYm= NX7tR3pOOSEQvF2g M2LHUVI1KGh? NEHnb3BGdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBUNXCqYYPlJIFzemW|dB?= Mk\pNVg6PTR5MUK=
L3 M{Lo[mN6fG:2b4jpZ{BCe3OjeR?= MXi1JO69VSB? NYPYOoZoQTZiaB?= NWHXR4M{TE2VTx?= MXHTbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHygd5Vzfmm4YXy= NXiyNYE4OjBzMkS0OVk>
Granta-519 MVTDfZRwfG:6aXOgRZN{[Xl? NUfF[4k{PSEQvF2g M4HMdVk3KGh? Mn[1SG1UVw>? MYLTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt MlvSNlAyOjR2NUm=
BT NGHEPIlEgXSxdH;4bYMhSXO|YYm= NF7uTmM2KM7:TTC= MXq5OkBp M1;BT2ROW09? NHjCVG9UdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu M2WydFIxOTJ2NEW5
UPN2 MkfuR5l1d3SxeHnjJGF{e2G7 Mn60OUDPxE1i NH24Ong6PiCq Mn;lSG1UVw>? NGnGPGlUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu NXjsV|BLOjBzMkS0OVk>
HBL-2 M2LXTmN6fG:2b4jpZ{BCe3OjeR?= M{TTNFUh|ryPIB?= NIDlWHE6PiCq M{XqVGROW09? M1TiTnNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? M3rJ[VIxOTJ2NEW5
JVM-2 MlrWR5l1d3SxeHnjJGF{e2G7 MXq1JO69VSB? MWi5OkBp NEPiTmhFVVOR M37VZXNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? M2i0O|IxOTJ2NEW5
Z138 NGTuOJNEgXSxdH;4bYMhSXO|YYm= NHG2cog2KM7:TTC= NHT2RnE6PiCq NV\xZ3JvTE2VTx?= MlzxV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? NHHldVUzODF{NES1PS=>
RWPE NWDSbHRJUW64YYPpeoUhSXO|YYm= NH3sRZozPSEQvF2= NYe4SotKPDhiaB?= NH3sfZFFVVOR Mo\IV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KEWURz3kdol3\W5iY3XscEBqdn[jc3nvci=> NFSwPW8zOTV5NUi2OS=>
VCaP M{i0cWlvfmG|aY\lJGF{e2G7 NYnsOmM2OjVizszN NFy5Rnk1QCCq MoXmSG1UVw>? NGL4Z|FUcWewaX\pZ4FvfGy7IILl[JVk\XNiRWLHMYRzcX[nbjDj[YxtKGmwdnHzbY9v NV7aNHBwOjF3N{W4OlU>
Mouse H2AX−/− ES Cells MlfjR5l1d3SxeHnjJGF{e2G7 M4W4OlIvPSEQvF2= NGDRSpQzOCCq NWPyXXI4W2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKHO3co\peoFt MlO0NlM{PTV2OEm=
Mouse ATM−/− ES Cells NX7V[lB{S3m2b4TvfIlkKEG|c3H5 M1XwPFIvPSEQvF2= MVWyNEBp NIX4eWRUcWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwhe3W{dnn2ZYw> Mon1NlM{PTV2OEm=
H1650 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVGyNXliOjBizszN NVTNT4x6OTR2IHi= NV3ENGl7UUN3ME2xOU41PyEQvF2= Mom0NlMzOzl6MEm=
H1650PTEN+ NULXfXRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYKyNEDPxE1? MXWxOFQhcA>? MojqTWM2OD13MD64N{DPxE1? MWCyN|I{QThyOR?=
PC-9 NHHSOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3r0UFIxKM7:TR?= MUexOFQhcA>? MYTJR|UxRTVwOEig{txO NEmxUVkzOzJ|OUiwPS=>
PC-9PTEN− MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGmxTZczOCEQvF2= M17BRlE1PCCq MU\JR|UxRTZwNUKg{txO MoTJNlMzOzl6MEm=
MDA-MB-231 NUXXOGM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYm1JIRigQ>? Mn3WTWM2OD14Lkmg{txO MUCyN|c3ODR7Nh?=
MDA-MB-468 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXK1JIRigQ>? MVfJR|UxRTVwMDFOwG0> MXSyN|c3ODR7Nh?=
BT20 M4rjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfN[HQ2KGSjeR?= NVTDNYJpUUN3ME23Mlch|ryP MYKyN|c3ODR7Nh?=
HCC1143 NHGy[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PLdVUh\GG7 MUTJR|UxRTFzLkGg{txO MYWyN|c3ODR7Nh?=
HCC1937 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEH3W5Y2KGSjeR?= MVjJR|UxRTF{Lk[g{txO MXuyN|c3ODR7Nh?=
Hs578t NHnhbo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DaOlUh\GG7 MmDLTWM2OD13Lk[g{txO NXviNm9HOjN5NkC0PVY>
Hs578t(si) M{T0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzrOUBl[Xl? M1G3W2lEPTB;Nz61JO69VQ>? MnzFNlM4PjB2OU[=
BT474 M3HOXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkK2OUBl[Xl? NIrISFZKSzVyPUG5Mlgh|ryP NFHUco8zOzd4MES5Oi=>
JIMT1 MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLJc2YxPSCmYYm= NV;DcJFlUUN3ME23Mlch|ryP MWiyN|c3ODR7Nh?=
SKBR3 NInMV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n1RVUh\GG7 MonNTWM2OD1zMT6xJO69VQ>? NFzKUXczOzd4MES5Oi=>
SUM159 NFe2cGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjVUnVvPSCmYYm= MmLaTWM2OD12LkKg{txO MWCyN|c3ODR7Nh?=
CAMA1 NFvPW4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHxOUBl[Xl? NF;zPW5KSzVyPUG1Mlgh|ryP MkXrNlM4PjB2OU[=
MCF7 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTFOUBl[Xl? M4r2S2lEPTB;NT64JO69VQ>? MmPtNlM4PjB2OU[=
T47D M{T4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4OyT|Uh\GG7 NYPoWGxLUUN3ME25MlYh|ryP NYLD[JhKOjN5NkC0PVY>
HCT116 Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jlcFExOCEQvF2= M2jtVVQ5KGh? NH\SOXVFVVOR MkjnTWM2OD1{LkWg{txOKA>? NFLTWlAzPDV5N{m0NS=>
SW1116 MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rpPVExOCEQvF2= NYTCVFU1PDhiaB?= NYjudoVvTE2VTx?= MX3JR|UxRTFyMDFOwG0> M3nLWVI1PTd5OUSx
HT29 NHfIfohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3XNVAxKM7:TR?= MmjoOFghcA>? NVnRTo4zTE2VTx?= MWnJR|UxRTF2Lkeg{txO NHvENXQzPDV5N{m0NS=>
LoVo M1v5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TWc|ExOCEQvF2= MkPsOFghcA>? Ml3LSG1UVw>? NW\vTFhlUUN3ME2xN{41KM7:TR?= M120N|I1PTd5OUSx
HCT-15 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU[xNFAh|ryP MVy0PEBp Ml3ZSG1UVw>? MYHJR|UxRTFyIN88US=> M3jiXVI1PTd5OUSx
SW48 NYHDWndqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV23WXJ[OTByIN88US=> NUTvO4wyPDhiaB?= MV\EUXNQ NHW1VYJKSzVyPUmuOUDPxE1? M3;yNFI1PTd5OUSx
C-1 NWHXO4lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[2cWs5OTByIN88US=> MXS0PEBp NWnnNnV{TE2VTx?= NYLod|NoUUN3ME23MlYh|ryP M3Ppb|I1PTd5OUSx
RKO MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3HeY5ROTByIN88US=> NIfOO4o1QCCq MkLUSG1UVw>? MnPzTWM2OD13Lkmg{txO NGXB[ZgzPDV5N{m0NS=>
HCT116 NVzOR5k{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LZclExOCEQvF2= NUK1[3NNPDhiaB?= NYrJbIhTTE2VTx?= MljEVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? NFnWRmIzPDV5N{m0NS=>
SW1116 M2DtOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DSOFExOCEQvF2= MUK0PEBp Mnu0SG1UVw>? M{XQOHBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? MmC0NlQ2Pzd7NEG=
HT29 M3TQcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[xNFAh|ryP MUO0PEBp NWfXcXV{TE2VTx?= MlXXVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? NV3SeYQ2OjR3N{e5OFE>
LoVo NYTQe3R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWGxNFAh|ryP NXLvOoR3PDhiaB?= M1\JN2ROW09? NIHIZWZRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli MXiyOFU4Pzl2MR?=
SW48 NVj0cmpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fWWlExOCEQvF2= NY\pVXNoPDhiaB?= NIDpc5FFVVOR MoS1VI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? M{\vO|I1PTd5OUSx
C-1 NV\oe|JsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2xNFAh|ryP NXfBWJdCPDhiaB?= MlG1SG1UVw>? MmezVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? MmroNlQ2Pzd7NEG=
RKO NGC1OWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XtclExOCEQvF2= MVG0PEBp NGnCPGlFVVOR NYq4TZJQWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= NWLmS5hkOjR3N{e5OFE>
HCT116 M361fWZ2dmO2aX;uJGF{e2G7 Mn3HNVAhdk1? M4qy[FEzKGh? NUTifWFWTE2VTx?= NIewc2FKdmO{ZXHz[ZMhTE6DIHTveYJt\S2|dILhcoQh[nKnYXvzJIlv\HWlZXSgZpkhW05vM{i= MVGyOFU4Pzl2MR?=
HT29 MU\GeY5kfGmxbjDBd5NigQ>? M3TBeFExKG6P MoHGNVIhcA>? MXnEUXNQ MYfJcoNz\WG|ZYOgSG5CKGSxdXLs[U1{fHKjbnSgZpJm[Wu|IHnu[JVk\WRiYomgV24uOzh? M1P3[FI1PTd5OUSx
TE-6 M2S2cmZ2dmO2aX;uJGF{e2G7 MVW1JO69VSB? NEHPfoYyOiCq MVjEUXNQ MkX2TY5lfWOnczDHNk9OKGG{cnXzeC=> NHL4WFIzPDJzOUG2OC=>
TE-6 NYHYOZlsTnWwY4Tpc44hSXO|YYm= NXy5VWZzPSEQvF2g NGTvN3AzPCCq NGDadVRFVVOR NYf1d3RiUW6lcnXhd4V{KGmwIHTveYJt\SC|dILhcoQh[nKnYXvzJEhFW0K|KR?= NHfsOnMzPDJzOUG2OC=>
Hep3B MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHSepA1OCEQvF2g NIXWTYo4OiCq NXrUdpRlTE2VTx?= Mk[zV5lv\XKpaYP0bYNidGy7IHnubIljcXS|IHPlcIwh\3Kxd4ToJJdqfGhiRFjNSXE> MmjNNlUxPzJ5NUK=
Huh7 NH25bGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\WOFAh|ryPIB?= NYe0OIY{PzJiaB?= M{XURmROW09? M2rDfXN6dmW{Z3nzeIlk[WyueTDpcohq[mm2czDj[YxtKGe{b4f0bEB4cXSqIFTIUWVS NYDZNYVLOjVyN{K3OVI>
Hep3B MnTnSpVv[3Srb36gRZN{[Xl? MUW0NEDPxE1i NVjnW3JiOjRiaB?= Mn3tSG1UVw>? NWfkRZM3UW6mdXPld{BTV1NicILv[JVkfGmxbjD3bZRpKESKTVXR NXH0eJNxOjVyN{K3OVI>
Huh7 NIDHTWVHfW6ldHnvckBCe3OjeR?= M4PBeFQxKM7:TTC= MlP3NlQhcA>? NGfQSZJFVVOR MmjaTY5lfWOnczDSU3MheHKxZIXjeIlwdiC5aYToJGRJVUWT NY\Ib2dLOjVyN{K3OVI>
Hep3B M{XKSmZ2dmO2aX;uJGF{e2G7 M2HxU|QxKM7:TTC= NG\S[nQzPCCq MknaSG1UVw>? MXfJcoR2[2W|IHPlcIwh[XW2b4DoZYd6KHerdHigSGhOTVF? NYq3UItvOjVyN{K3OVI>
Huh7 NVL3dIMxTnWwY4Tpc44hSXO|YYm= NVPmfZRyPDBizszNJC=> MoLFNlQhcA>? MnzaSG1UVw>? NHK2V2ZKdmS3Y3XzJINmdGxiYYX0c5Bp[We7IIfpeIghTEiPRWG= NX63TJB4OjVyN{K3OVI>
SGC-7901 MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\UN|DDqM7:TR?= NXjyWIVnPDhiaB?= M1zwNGROW09? NUPSW4diSmyxY3ugc5hidGmybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp MVyyOVc3PzB5Nh?=
COLO-800 M2PQUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlOzTWM2OD1yLkS0NVY1KM7:TR?= NV\hPYpJW0GQR1XS
EoL-1- NI\JdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3zUlRKSzVyPUCuOVY1PDZizszN M4XifHNCVkeHUh?=
NCI-H209 NHX0OJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHKyU|NKSzVyPUCuPVE2PTZizszN MYPTRW5ITVJ?
ES1 Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTFwMUG0NFgh|ryP MVLTRW5ITVJ?
NKM-1 M2fISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\oTWM2OD1zLkK1N|Q4KM7:TR?= Ml;6V2FPT0WU
NTERA-S-cl-D1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTFwM{OzOFEh|ryP Ml3JV2FPT0WU
MHH-ES-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXnTWM2OD1zLk[yNFY4KM7:TR?= NXG3eWxPW0GQR1XS
ES8 MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHBSZpKSzVyPUGuO|I1OTRizszN M2r0dXNCVkeHUh?=
NCI-H720 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPZSoJKSzVyPUKuNlA3QTlizszN NH\xcWNUSU6JRWK=
EW-3 NGjlPXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\oSYlMUUN3ME2yMlI4PTN2IN88US=> NWK0bIp5W0GQR1XS
D-566MG M1\Yfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ewdWlEPTB;Mj60OFU3QCEQvF2= NV70RnUxW0GQR1XS
697 MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrVOVBtUUN3ME2yMlg1OTd|IN88US=> NVvLUmNHW0GQR1XS
ES5 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTJwOEixPFkh|ryP NGLBUI9USU6JRWK=
COLO-684 Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjV[IdyUUN3ME2zMlUyPjl4IN88US=> MlL0V2FPT0WU
ML-2 M2rOUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PsOWlEPTB;Mz62NFA2QCEQvF2= NWHwU|l1W0GQR1XS
MC-IXC NFTIO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTESGpKSzVyPUOuOlM{QTNizszN M3HSZXNCVkeHUh?=
DB M1zkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXCPYlKSzVyPUOuOlU1PDhizszN NGe2cpFUSU6JRWK=
HCC2218 M3nuNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHBPYxKSzVyPUOuO|MyODNizszN M2jJdHNCVkeHUh?=
NCI-H510A M4PjfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVy2dWg4UUN3ME2zMlgzPzJ2IN88US=> MVXTRW5ITVJ?
NCI-H526 Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTNwOE[5OVgh|ryP MV7TRW5ITVJ?
MV-4-11 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PBdmlEPTB;ND6xN|M{PCEQvF2= Ml;XV2FPT0WU
PA-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHj4U4NKSzVyPUSuNlUzQSEQvF2= NWjT[nQyW0GQR1XS
EW-22 NVrzS2hsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW2TWM2OD12LkO1PFYh|ryP M{PJeXNCVkeHUh?=
KASUMI-1 NI\SbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHaOJN5UUN3ME20MlQxOTB7IN88US=> NUiw[Y9yW0GQR1XS
LU-139 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFK3RlVKSzVyPUSuO|U5OjlizszN MVfTRW5ITVJ?
SBC-1 MonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf0TWM2OD12LkiwPVA5KM7:TR?= MWXTRW5ITVJ?
H4 MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvwe2VKSzVyPUSuPFk1PDNizszN MXrTRW5ITVJ?
EW-11 NFfBZ2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{ThfGlEPTB;NT6wPFA4OiEQvF2= Ml\NV2FPT0WU
NBsusSR MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzoTWM2OD13LkGyNFU2KM7:TR?= NV\aNYo1W0GQR1XS
RPMI-8226 M2nJd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PV[GlEPTB;NT6xOVI1PCEQvF2= M37QfHNCVkeHUh?=
DEL M3m3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHHb2RKSzVyPUWuNlAxODZizszN NFnBN4NUSU6JRWK=
ES4 NXrNTFBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULQNoQ1UUN3ME21MlUyOzh7IN88US=> NHTMZmdUSU6JRWK=
GCT Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTVwNU[4OVYh|ryP MUPTRW5ITVJ?
NCI-H1048 MonrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTVwOUeyO|Mh|ryP Moj6V2FPT0WU
NCI-SNU-1 M{HZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFOxUnBKSzVyPU[uNFIzKM7:TR?= NXjBT|ZSW0GQR1XS
ES7 MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfyXI1KSzVyPU[uNFM2PzdizszN NIK5UoJUSU6JRWK=
SW982 MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q0NmlEPTB;Nj6wPVE{PyEQvF2= MWrTRW5ITVJ?
L-363 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULQW2JZUUN3ME22MlM{QTd2IN88US=> MnvXV2FPT0WU
HT-1080 M2\qSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\ES2lEPTB;Nj60PVY5OyEQvF2= MWLTRW5ITVJ?
HAL-01 Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjaUXFLUUN3ME22MlUyODlizszN MnfmV2FPT0WU
NB14 M4nEbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELNPZlKSzVyPU[uOlQxOzlizszN M1HRbnNCVkeHUh?=
EW-13 NULqOJgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTZwN{e0NlQh|ryP MX\TRW5ITVJ?
NY NHmySYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTZwOUS2NFUh|ryP M2[xTnNCVkeHUh?=
NCI-SNU-5 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPYTWM2OD15LkGwOFM{KM7:TR?= NU\Sc41tW0GQR1XS
MS-1 NYHM[lBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTdwMUe0PVQh|ryP NHXjPI1USU6JRWK=
EW-16 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTtTWM2OD15LkOxPFYyKM7:TR?= MXHTRW5ITVJ?
LU-65 M2XrUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrPTWM2OD15LkS4OFE4KM7:TR?= M1HNXHNCVkeHUh?=
HGC-27 M4H4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1exfWlEPTB;Nz63NlE4OyEQvF2= NW\1[20zW0GQR1XS
CTB-1 NF\BeolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXQ[mJKSzVyPUeuO|YyPzVizszN M4DhRnNCVkeHUh?=
5637 M3e0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXyVnFKSzVyPUeuPVI5PiEQvF2= M3rNNHNCVkeHUh?=
U251 NITpcIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\C[VA5UUN3ME23Mlk1ODF4IN88US=> NWfXSYpKW0GQR1XS
HOS NVLnNotmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRThwMkOwNFch|ryP NVy0VnNuW0GQR1XS
DOHH-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f3WWlEPTB;OD6yN|U5KM7:TR?= MmWzV2FPT0WU
EW-1 NFrxbmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7PTWM2OD16LkOwNFg5KM7:TR?= MUDTRW5ITVJ?
BV-173 Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTCbHFzUUN3ME24MlU2PTRizszN M2jZSHNCVkeHUh?=
8-MG-BA NVvueW41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\YTWM2OD16Lk[4PVg5KM7:TR?= MWfTRW5ITVJ?
NB69 NVnsdGV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzwN5lKSzVyPUiuO|A6OjFizszN MXPTRW5ITVJ?
NCI-H69 M{HXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTlwOUC5OlEh|ryP MlS5V2FPT0WU
RS4-11 NHG3UJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDZTWM2OD1zMT6yNlA5KM7:TR?= NFH3do1USU6JRWK=
ONS-76 NY\DT3V7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzBS3RyUUN3ME2xNU4zQTR5IN88US=> NVewRXFbW0GQR1XS
SF539 M2\xdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTFTWM2OD1zMT60PFg6KM7:TR?= M3LNW3NCVkeHUh?=
HuO-3N1 Mn;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFzLkW3PVYh|ryP M2HDWHNCVkeHUh?=
NCI-H1651 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjLcoVKSzVyPUGyMlMyOTVizszN MXrTRW5ITVJ?
KARPAS-45 MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEe5XGVKSzVyPUGyMlM4PiEQvF2= NEXSR3VUSU6JRWK=
SK-NEP-1 Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTF{LkS2NFkh|ryP M{\EbHNCVkeHUh?=
LAMA-84 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrST5ppUUN3ME2xN{4yODl3IN88US=> MofzV2FPT0WU
NCI-H1155 NIn5TXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHUVZFnUUN3ME2xN{4zQDV4IN88US=> NUnZfXExW0GQR1XS
CTV-1 NVfWWnpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTF|LkS0OUDPxE1? MYjTRW5ITVJ?
QIMR-WIL M{LDNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjNTWM2OD1zMz63PFE1KM7:TR?= MWHTRW5ITVJ?
H9 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLlTotKSzVyPUGzMlg1PzVizszN MnTjV2FPT0WU
SK-MEL-1 M3:wSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTF|LkmzOFch|ryP MmXSV2FPT0WU
HD-MY-Z MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEj5ZYFKSzVyPUG0MlA3OzdizszN NUDKPJNNW0GQR1XS
TI-73 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF2LkKzOVYh|ryP M1H6NnNCVkeHUh?=
JVM-3 M4jpdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTF3LkW3NVYh|ryP NWXFXnlZW0GQR1XS
D-247MG M1nMS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;2SHJjUUN3ME2xOU42QTNizszN Mlf6V2FPT0WU
VA-ES-BJ NFvWVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVztWJNEUUN3ME2xOU43ODl5IN88US=> MXTTRW5ITVJ?
NOS-1 Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\OOHJKSzVyPUG1MlY2OjJizszN NHPWcItUSU6JRWK=
MOLT-4 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;qWYtoUUN3ME2xOk44PTJizszN NGftVFBUSU6JRWK=
Mo-T M1n1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF5LkC4OFkh|ryP MXPTRW5ITVJ?
NCI-H1770 NHfZfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z0cGlEPTB;MUeuNVU1OyEQvF2= MVHTRW5ITVJ?
COLO-320-HSR Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrNbGpZUUN3ME2xO{4yQDJ5IN88US=> MlHJV2FPT0WU
TE-12 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr4bpZ[UUN3ME2xO{44ODV2IN88US=> Mn7kV2FPT0WU
NCI-H82 M3vuZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH3cYxxUUN3ME2xO{45PzJ6IN88US=> NHXJ[HZUSU6JRWK=
NEC8 NYPISIFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULxNWhiUUN3ME2xPE4yOzF4IN88US=> NGr4XmNUSU6JRWK=
HSC-3 M{PVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF6Lke0NVQh|ryP MmP6V2FPT0WU
NCI-H1092 NXrFbFdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzQTWM2OD1zOD63OVk2KM7:TR?= M{C4NnNCVkeHUh?=
NCI-H292 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L1RmlEPTB;MUmuNFQ5QSEQvF2= MXPTRW5ITVJ?
L-428 M1rTUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF7LkW1PUDPxE1? Mo\NV2FPT0WU
LU-134-A NUTWT|JjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYW4W5g{UUN3ME2xPU42PzJizszN MlvQV2FPT0WU
GI-ME-N NXjqfmdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXSxfGtWUUN3ME2xPU42PzR5IN88US=> M2m0WXNCVkeHUh?=
ALL-PO MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF7LkW5O|Ih|ryP NXrMOlR4W0GQR1XS
D-283MED NXjxUY9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTpV|ZkUUN3ME2xPU46OTVizszN NInoc2xUSU6JRWK=
D-423MG M{j1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7USFZKSzVyPUG5Mlk6PjdizszN M{fVZ3NCVkeHUh?=
CAKI-1 NEXzV4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJyLkKyNVkh|ryP M2fDZXNCVkeHUh?=
ETK-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rzWGlEPTB;MkCuNlYyPSEQvF2= NH2x[VZUSU6JRWK=
G-402 NIm3eplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJyLkWzN|Qh|ryP NV7v[W9oW0GQR1XS
HL-60 MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJzLkG2NVMh|ryP MVPTRW5ITVJ?
A2058 M2DaXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJzLkS0O|ch|ryP NUXoXmxIW0GQR1XS
CHP-212 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml20TWM2OD1{MT65NFUyKM7:TR?= MWjTRW5ITVJ?
KY821 NFLJUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1izXWlEPTB;MkGuPVc2KM7:TR?= M2TYNXNCVkeHUh?=
TYK-nu NWrreJlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTsTHdKSzVyPUKyMlA3PTFizszN M3qw[nNCVkeHUh?=
JVM-2 M3vVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUi4eHV5UUN3ME2yNk4zQTh|IN88US=> M1PFVnNCVkeHUh?=
KU812 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTJ{LkezNVIh|ryP MkC2V2FPT0WU
MKN28 MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTkTWM2OD1{Mj65NFE2KM7:TR?= MYLTRW5ITVJ?
ECC10 M1zIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjKOmpkUUN3ME2yN{44PDFizszN NYiwXGlPW0GQR1XS
BHT-101 NInQcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTHfYpKSzVyPUK0MlAxODhizszN MWnTRW5ITVJ?
DU-4475 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\4[m9KSzVyPUK0MlM{OzdizszN NWGyPZZGW0GQR1XS
769-P MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJ2Lki0OlYh|ryP NV\rdog{W0GQR1XS
HEC-1 NIT1eo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XBdmlEPTB;MkWuOFQ2KM7:TR?= MmL4V2FPT0WU
MOLT-13 NVrESnhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fCdGlEPTB;MkWuOVM{OSEQvF2= MWjTRW5ITVJ?
8505C NFnINHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJ4LkS5O|ch|ryP NIPjWHJUSU6JRWK=
GB-1 NFX1bYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJ4LkexO|Yh|ryP MXvTRW5ITVJ?
SF126 M13IfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nvXWlEPTB;Mk[uO|Y1QCEQvF2= M4G2UnNCVkeHUh?=
A4-Fuk NV\zTo0zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2H5SmlEPTB;MkeuNVI4OSEQvF2= M2f5ZnNCVkeHUh?=
OVCAR-8 NFTYO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLxTWM2OD1{Nz6xOVM6KM7:TR?= MWTTRW5ITVJ?
NCI-H1304 NX\FT2tIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLUTWM2OD1{Nz61OEDPxE1? NIDsV3ZUSU6JRWK=
GR-ST MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHo[3VKSzVyPUK4MlA1PyEQvF2= NUjHd45jW0GQR1XS
G-401 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXnSmhKSzVyPUK4MlUxQTZizszN M1j0UnNCVkeHUh?=
LXF-289 NX7NOG57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTmSodWUUN3ME2yPE42PjVzIN88US=> MoG2V2FPT0WU
DBTRG-05MG MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M36wS2lEPTB;MkiuPVIxPCEQvF2= M1HRPXNCVkeHUh?=
YKG-1 M1iwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HCVWlEPTB;MkmuPFY5KM7:TR?= NUDmbWU6W0GQR1XS
GAMG NUe2b|hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHuNItTUUN3ME2yPU46QTNizszN MVvTRW5ITVJ?
HCT-116 NEnNU2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7RNHhKSzVyPUOwMlA2PDhizszN MkjGV2FPT0WU
S-117 NHrCVG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi2TWM2OD1|MT6yNlU4KM7:TR?= MYjTRW5ITVJ?
NCI-H1693 M4D1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jHUGlEPTB;M{OuOlU1OiEQvF2= MUjTRW5ITVJ?
A427 MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\PbGlEPTB;M{OuPVk4PiEQvF2= M17wdnNCVkeHUh?=
HT-29 M1L0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXuTWM2OD1|ND62NFMzKM7:TR?= M{nITnNCVkeHUh?=
P12-ICHIKAWA Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTN2Lke0PVEh|ryP MV3TRW5ITVJ?
CAL-51 Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\LVItrUUN3ME2zOU4xPzB7IN88US=> MYPTRW5ITVJ?
Ramos-2G6-4C10 NV7aZ4twT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnETWM2OD1|NT6yOFI2KM7:TR?= NHzqUY5USU6JRWK=
SCH M{DOeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M176WmlEPTB;M{[uOFE4PCEQvF2= M2TWVXNCVkeHUh?=
SK-MEL-24 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPjTWM2OD1|Nj65NFQ1KM7:TR?= NIPR[INUSU6JRWK=
SW1573 MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrrZY1KSzVyPUO4MlczOTZizszN MXvTRW5ITVJ?
BALL-1 NX;uXnRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzIZlFxUUN3ME2zPU4zOTJ7IN88US=> NUXOb4NZW0GQR1XS
BE-13 M4POVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof2TWM2OD1|OT6zNlkh|ryP MlPXV2FPT0WU
GI-1 NYfSZXQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXqbYlPUUN3ME2zPU45PjR5IN88US=> M4[4RXNCVkeHUh?=
GOTO MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7Yd5h6UUN3ME2zPU46OTN7IN88US=> M33oRXNCVkeHUh?=
A673 MnuzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTRzLkCzOFMh|ryP NYDTW20yW0GQR1XS
KG-1 NV3iN2NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{W1S2lEPTB;NEOuN|k1KM7:TR?= MWXTRW5ITVJ?
GP5d MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLaTWM2OD12ND6wOlY3KM7:TR?= MlvhV2FPT0WU
MFM-223 MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2H6ZmlEPTB;NESuNVIzQCEQvF2= Mm\nV2FPT0WU
OAW-42 NYXRb4t[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\RZXJ2UUN3ME20OE4zPjR|IN88US=> M3zNenNCVkeHUh?=
C8166 NYX6b|hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nzZWlEPTB;NEWuNFgzOiEQvF2= MkHrV2FPT0WU
LU-99A MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnUTWM2OD12Nj6xN|IzKM7:TR?= Mk\qV2FPT0WU
NCI-H23 NF7ieGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTR4LkG3PFUh|ryP MU\TRW5ITVJ?
HO-1-N-1 NV3ZW2VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorjTWM2OD12Nz6wPVk5KM7:TR?= NGLDN29USU6JRWK=
A3-KAW M{XJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjhNphZUUN3ME20O{4yODB5IN88US=> NGHCSHhUSU6JRWK=
CGTH-W-1 NHPvWZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7VTWM2OD12Nz61NFY6KM7:TR?= MVHTRW5ITVJ?
DJM-1 MlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLiTWM2OD12Nz61OFE{KM7:TR?= M1LvfXNCVkeHUh?=
A101D NWfPcGNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUO0O5ZJUUN3ME20O{43OzV5IN88US=> M{ToUXNCVkeHUh?=
BB30-HNC NGfGUmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK5TWhKSzVyPUS4MlMxPzJizszN NWTlPVl{W0GQR1XS
T98G MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknsTWM2OD12OD60OlM{KM7:TR?= MWrTRW5ITVJ?
NCI-H1573 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjr[oJKSzVyPUS5MlQ1PjJizszN MljNV2FPT0WU
MEG-01 M2Tvd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu2V|BEUUN3ME20PU44PDFzIN88US=> NVjjb3JpW0GQR1XS
WM-115 NEPGN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HKZmlEPTB;NEmuPVIzOiEQvF2= Mmq1V2FPT0WU

... Click to View More Cell Line Experimental Data

体内研究 Olaparib有效作用于Brca1-/-;p53-/- 乳腺肿瘤 (每天按50 mg/kg剂量腹腔注射),但是对 HR缺陷的Ecad-/-;p53-/-乳腺肿瘤没有效果。Olaparib作用于携带肿瘤的鼠没有剂量限制毒性。[3] Olaparib已经用于治疗BRCA突变的肿瘤, 比如卵巢癌,胸腺癌,前列腺癌。此外,Olaparib抑制ATM缺陷的肿瘤细胞具有选择性,说明Olaparib可作为治疗ATM突变的淋巴肿瘤的潜在试剂。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

体外独立酶实验:

通过PARP-1实验测定PARP-2抑制活性,实验在96孔板上进行,PARP-2特定抗体与重组PARP-2蛋白结合。加入3H-NAD+DNA测定PARP-2活性。 冲洗后,加入闪烁剂测定3H-渗透的核糖基化。通过AlphaScreen实验测定端锚聚合酶-1, 实验中HIS标签重组TANK-1蛋白和生物素化的NAD+ 在384孔Proxi板上温育。 加入Alpha 磁珠,与HIS和生物素化的标签结合,产生邻近信号,测定信号消失的比例来计算TANK-1抑制活性。
细胞实验:

[1]

+ 展开
  • Cell lines: 胸腺癌细胞系SW620结肠, A2780卵巢,HCC1937,Hs578T,MDA-MB-231,MDA-MB-436,和T47D
  • Concentrations: 1到300 nM
  • Incubation Time: 7-14天
  • Method:

    通过成株实验测定Olaparib毒性。Olaparib溶于DMSO中,用培养基稀释。细胞接种在六孔板上,过夜使粘附。然后加入不同浓度Olaparib,温育7-14天。计算存活菌落,测定IC50值。


    (Only for Reference)
动物实验:

[3]

+ 展开
  • Animal Models: 携带Brca1-/-;p53-/-乳腺癌的 K14cre;Brca1F/F;p53F/F
  • Formulation: 50 mg/mL储存在含10% 2-羟丙基-β-环糊精/PBS的DMSO中
  • Dosages: 50 mg/kg
  • Administration: 按10 μL/g剂量腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
4% DMSO+30% PEG 300+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 434.46
化学式

C24H23FN4O3

CAS号 763113-22-0
稳定性 powder
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01758731 Active, not recruiting Squamous Cell Carcinoma of the Head and Neck University of Colorado, Denver July 9, 2012 Phase 1
NCT02484404 Recruiting Lung Cancer|Breast Cancer|Ovarian Cancer|Colorectal Cancer|Prostate Cancer|Triple Negative Breast Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) June 4, 2015 Phase 1|Phase 2
NCT02769962 Recruiting Solid Tumors|Small Cell Lung Carcinoma|Carcinoma, Non-Small-Cell Lung|Lung Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 3, 2016 Phase 1|Phase 2
NCT01237067 Completed Cervical Cancer|Ovarian Cancer|Breast Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Endometrial Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2010 Phase 1
NCT00678132 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 24, 2008 Phase 1
NCT02121990 Active, not recruiting Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer Memorial Sloan Kettering Cancer Center|AstraZeneca|Genentech, Inc. April 21, 2014 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • 回答:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • 问题 2:

    How long can the chemical compound be stable in DMEM at 4 ℃?

  • 回答:

    The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

相关PARP产品

Tags: 购买Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436)供应商 | 采购Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436)价格 | Olaparib (AZD2281, Ku-0059436)生产 | 订购Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID